Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Helical tomotherapy with concurrent docetaxel and cisplatin for unresectable stage III non-small cell lung cancer
2006-003708-21Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2006
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and cisplatin in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Dose-limiting toxicity during radiation dose escalation. Started Oct 2006; status: completed.
02
Drugs
docetaxelcisplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2006-003708-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003708-21.